Uncategorized
GSK ends brain drug alliance with Alector

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK’s return to neuroscience.
Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK’s return to neuroscience.